Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T14-targeting ASO
- Development stage
- Preclinical
- Lead developer
- Neuro-Bio-Tech
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Neuro-Bio is developing a T14-targeting antisense oligonucleotide (ASO) as an RNA-based therapy for Alzheimer's disease and other neurodegenerative conditions. The therapeutic is designed to target and reduce the expression of T14, a 14-amino acid peptide derived from the C-terminus of acetylcholinesterase (AChE). Neuro-Bio's research suggests that T14 is a toxic signaling molecule that drives neurodegeneration in the adult brain. By using an ASO to block the production of this peptide at the genetic level, the company aims to halt the progression of Alzheimer's disease. The program is currently in the preclinical stage of development.
- Other names
- T14-targeting RNA-based therapyT-14-targeting RNA-based therapyT 14-targeting RNA-based therapyNeuro-Bio T14 ASOT14 ASOT-14 ASOT 14 ASO
02
Targets
Acetylcholinesterase
Beyond the preview
Go deeper on T14-targeting ASO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T14-targeting ASO.